Valneva’s Lyme disease vaccine faces final clinical test in a sparse landscape
Pharmaceutical Technology
AUGUST 17, 2022
On August 8, Pfizer and Valneva announced the initiation of a Phase III study with their Lyme disease vaccine , bringing the prospect of an injection to prevent the condition disease one step closer to reality. cases per 100,000 people in 2018. “In In the UK, the mean annual incidence of Lyme disease grew from 0.38
Let's personalize your content